Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company
Executive Summary
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
You may also be interested in...
McKinsey’s Push For Class-Wide Opioid REMS Among Actions Targeted In Opioid Settlement
Consulting firm agrees to turn over tens of thousands of documents detailing its advice to Purdue, J&J, Endo and Mallinckrodt and pay $537m as part of a deal with 47 states.
Sacklers Pressed At House Hearing To Return Billions Withdrawn From Purdue
Sackler family members were excoriated for taking $10.4 bn from Purdue after 2007 settlement with the DOJ but it seems unlikely the hearing will have an impact on bankruptcy proceedings. Asked to forego $3m bonus, Purdue CEO says he has already made "significant monetary concessions.”
Pharma Companies Urged To Stop In-Person Speaker Programs In HHS OIG ‘Special Fraud Alert’
Companies should consider alternatives to in-person physician presentations given the risk of kickback violations, OIG says. Concerns addressed in Novartis corporate integrity agreement are broader than that case, Chief Counsel to the Inspector General Greg Demske explains in an interview.